Last reviewed · How we verify
Calcijex
At a glance
| Generic name | Calcijex |
|---|---|
| Sponsor | Abbott |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Local Use of Vitamin D on the Rate of Canine Distillization: a Split Mouth Randomized Control Trial (PHASE1)
- Effects of Vitamin D in Patients Undergoing Fixed Orthodontic Mechanotherapy (NA)
- Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System (PHASE1)
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (PHASE3)
- Calcitriol Monotherapy for X-Linked Hypophosphatemia (EARLY_PHASE1)
- Clinical Evaluation of Local Calcitriol Delivery on Maxillary Canine Retraction (NA)
- Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (PHASE2)
- FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcijex CI brief — competitive landscape report
- Calcijex updates RSS · CI watch RSS
- Abbott portfolio CI